Qiagen (NYSE:QGEN) Stock Rating Cut to “Hold” at DZ Bank

DZ Bank cut shares of Qiagen (NYSE:QGEN) from a strong-buy rating to a hold rating in a research note published on Thursday,Zacks reports.

A number of other equities research analysts also recently weighed in on QGEN. Robert W. Baird raised their price target on shares of Qiagen from $50.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday. Weiss Ratings upgraded shares of Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 11th. Citigroup reissued a “neutral” rating and issued a $45.00 price objective (up from $38.00) on shares of Qiagen in a research note on Monday, August 10th. UBS Group assumed coverage on shares of Qiagen in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $47.00 target price on the stock. Finally, Kepler Capital Markets set a $38.60 target price on shares of Qiagen and gave the stock a “hold” rating in a research note on Thursday, June 25th. Four analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat.com, Qiagen currently has an average rating of “Hold” and a consensus target price of $44.43.

Qiagen Stock Up 0.4%

Shares of QGEN stock opened at $50.42 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. Qiagen has a one year low of $32.53 and a one year high of $57.81. The stock has a market cap of $10.39 billion, a P/E ratio of 25.83, a price-to-earnings-growth ratio of 4.99 and a beta of 0.61. The stock has a fifty day moving average price of $44.44 and a 200 day moving average price of $40.64.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.02. The business had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. Qiagen’s revenue was up .2% compared to the same quarter last year. During the same period last year, the firm posted $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. Analysts predict that Qiagen will post 2.44 earnings per share for the current year.

Hedge Funds Weigh In On Qiagen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hilltop National Bank bought a new position in Qiagen during the 2nd quarter worth $50,000. Integrated Wealth Concepts LLC acquired a new position in Qiagen during the 2nd quarter worth about $59,000. Allworth Financial LP grew its position in shares of Qiagen by 20.8% in the 2nd quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock valued at $72,000 after buying an additional 317 shares during the last quarter. denkapparat Operations GmbH bought a new stake in shares of Qiagen in the 2nd quarter valued at about $105,000. Finally, EverSource Wealth Advisors LLC grew its position in shares of Qiagen by 46.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock valued at $110,000 after buying an additional 876 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen updated third-quarter 2026 guidance to adjusted EPS of $0.65 and revenue of $548 million, above consensus estimates of $0.62 and $534.1 million, respectively. The figures are consistent with the company’s preliminary results and signal better-than-expected operating performance.
• Positive Sentiment: EQT agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share. The takeover provides a defined valuation and has been unanimously accepted, with the transaction nearing completion. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Robert W. Baird raised its price target to $52 from $50 and upgraded the stock to “outperform,” citing potential value near the takeover consideration. Robert W. Baird Qiagen rating
• Neutral Sentiment: Unusually heavy call-option activity suggests increased short-term trading interest, with call purchases roughly doubling typical volume, but it does not establish a fundamental change in valuation.
• Neutral Sentiment: JPMorgan reaffirmed its “neutral” rating while lowering its price target to $52 from $55, leaving limited projected upside relative to the current trading level. JPMorgan Qiagen rating
• Negative Sentiment: Law firms Brodsky & Smith and Halper Sadeh announced investigations into whether Qiagen obtained a fair price for shareholders. Such reviews could create deal uncertainty, although they do not currently indicate that the transaction will be blocked. Brodsky & Smith shareholder investigation

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.